Pulmatrix, Inc. (PULM:NASDAQ) closed at $1.33 on November 3, 2026, down 5.00% on the day. The stock trades 73.3% below its 52-week high of $4.99 and 14.7% above its 52-week low of $1.16. Over the past year, it lost 71.3%. Pulmatrix, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 3, 2025, PULM closed higher on 114 days (45%). Its best day was September 21, 2026 (+16.67%) and its worst was March 2, 2026 (-36.79%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 2 times.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Find more stocks like PULM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.